Cargando…

Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study

INTRODUCTION: Colon cancer impacts the lives of Kansans and those across the United States. Epidermal growth factor receptor (EGFR) inhibitors, such as panitumumab and cetuximab, have gained popularity as first-line treatment for stage 4 colon cancer despite their toxicities and have been used by cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Braden M., Pham, Tony A., Young, Kate J., Bantis, Leonidas E., Sun, Weijing, Kasi, Anup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: University of Kansas Medical Center 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409940/
https://www.ncbi.nlm.nih.gov/pubmed/36042840
http://dx.doi.org/10.17161/kjm.vol15.15975
_version_ 1784774973314826240
author Johnson, Braden M.
Pham, Tony A.
Young, Kate J.
Bantis, Leonidas E.
Sun, Weijing
Kasi, Anup
author_facet Johnson, Braden M.
Pham, Tony A.
Young, Kate J.
Bantis, Leonidas E.
Sun, Weijing
Kasi, Anup
author_sort Johnson, Braden M.
collection PubMed
description INTRODUCTION: Colon cancer impacts the lives of Kansans and those across the United States. Epidermal growth factor receptor (EGFR) inhibitors, such as panitumumab and cetuximab, have gained popularity as first-line treatment for stage 4 colon cancer despite their toxicities and have been used by clinicians in later lines of therapy. EGFR inhibitors have been proven to be an efficacious first-line treatment for stage 4 colon cancer, but no study has investigated outcomes comparing EGFR inhibitors as first-line treatment to its use as second- or third-line treatment. This study investigated EGFR inhibitor therapy estimated overall survival when used as first-, second-, and third-line treatment for stage 4 colon cancer. METHODS: A retrospective review was done for patients with stage 4 colon cancer who underwent EGFR inhibitor treatment at a large academic center from November 2007 to August 2021. The patients were stratified into five groups by the line in which they received the EGFR inhibitor treatment. A log-rank test was used to analyze the groups, and the median survival for each group was determined. RESULTS: A total of 68 patients were reviewed; 18 received first-line, 23 received second-line, 18 received third-line, 6 received fourth-line, and 3 received sixth-line treatment with an EGFR inhibitor. Fourth- and sixth-line therapies were excluded due to small patient size. There was no significant difference in estimated survival time between any of the lines. Median survival of the therapies was found. CONCLUSIONS: There was no statistical difference in survival between the first-, second-, or third-line groups, which may provide justification for its use as a second- or third-line therapy.
format Online
Article
Text
id pubmed-9409940
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher University of Kansas Medical Center
record_format MEDLINE/PubMed
spelling pubmed-94099402022-08-29 Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study Johnson, Braden M. Pham, Tony A. Young, Kate J. Bantis, Leonidas E. Sun, Weijing Kasi, Anup Kans J Med Original Research INTRODUCTION: Colon cancer impacts the lives of Kansans and those across the United States. Epidermal growth factor receptor (EGFR) inhibitors, such as panitumumab and cetuximab, have gained popularity as first-line treatment for stage 4 colon cancer despite their toxicities and have been used by clinicians in later lines of therapy. EGFR inhibitors have been proven to be an efficacious first-line treatment for stage 4 colon cancer, but no study has investigated outcomes comparing EGFR inhibitors as first-line treatment to its use as second- or third-line treatment. This study investigated EGFR inhibitor therapy estimated overall survival when used as first-, second-, and third-line treatment for stage 4 colon cancer. METHODS: A retrospective review was done for patients with stage 4 colon cancer who underwent EGFR inhibitor treatment at a large academic center from November 2007 to August 2021. The patients were stratified into five groups by the line in which they received the EGFR inhibitor treatment. A log-rank test was used to analyze the groups, and the median survival for each group was determined. RESULTS: A total of 68 patients were reviewed; 18 received first-line, 23 received second-line, 18 received third-line, 6 received fourth-line, and 3 received sixth-line treatment with an EGFR inhibitor. Fourth- and sixth-line therapies were excluded due to small patient size. There was no significant difference in estimated survival time between any of the lines. Median survival of the therapies was found. CONCLUSIONS: There was no statistical difference in survival between the first-, second-, or third-line groups, which may provide justification for its use as a second- or third-line therapy. University of Kansas Medical Center 2022-08-22 /pmc/articles/PMC9409940/ /pubmed/36042840 http://dx.doi.org/10.17161/kjm.vol15.15975 Text en © 2022 The University of Kansas Medical Center https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Research
Johnson, Braden M.
Pham, Tony A.
Young, Kate J.
Bantis, Leonidas E.
Sun, Weijing
Kasi, Anup
Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study
title Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study
title_full Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study
title_fullStr Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study
title_full_unstemmed Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study
title_short Epidermal Growth Factor Receptor Inhibitor Treatment Timing does not Impact Survival in Stage 4 Colon Cancer Treatment: A Retrospective Study
title_sort epidermal growth factor receptor inhibitor treatment timing does not impact survival in stage 4 colon cancer treatment: a retrospective study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409940/
https://www.ncbi.nlm.nih.gov/pubmed/36042840
http://dx.doi.org/10.17161/kjm.vol15.15975
work_keys_str_mv AT johnsonbradenm epidermalgrowthfactorreceptorinhibitortreatmenttimingdoesnotimpactsurvivalinstage4coloncancertreatmentaretrospectivestudy
AT phamtonya epidermalgrowthfactorreceptorinhibitortreatmenttimingdoesnotimpactsurvivalinstage4coloncancertreatmentaretrospectivestudy
AT youngkatej epidermalgrowthfactorreceptorinhibitortreatmenttimingdoesnotimpactsurvivalinstage4coloncancertreatmentaretrospectivestudy
AT bantisleonidase epidermalgrowthfactorreceptorinhibitortreatmenttimingdoesnotimpactsurvivalinstage4coloncancertreatmentaretrospectivestudy
AT sunweijing epidermalgrowthfactorreceptorinhibitortreatmenttimingdoesnotimpactsurvivalinstage4coloncancertreatmentaretrospectivestudy
AT kasianup epidermalgrowthfactorreceptorinhibitortreatmenttimingdoesnotimpactsurvivalinstage4coloncancertreatmentaretrospectivestudy